Pharmaceutical - Markets & Marketing, Abbott Laboratories

Filter

Popular Filters

India’s patents moves could see particular uncertainty for diabetes sector

India’s patents moves could see particular uncertainty for diabetes sector

17-02-2014

The Indian government's decision to review patented drugs by multinationals, to allow for the manufacture…

Abbott LaboratoriesAsia-PacificDiabetesEli LillyIndiaMarkets & MarketingMerck & CoNovo NordiskPatentsPharmaceutical

Patient trust in drugmakers declining, new report shows

14-01-2013

Increasing numbers of pharmaceutical companies are seeking to redefine their relationships with patients,…

Abbott LaboratoriesBiotechnologyEli LillyGilead SciencesGlaxoSmithKlineGlobalJanssenLundbeckMarkets & MarketingNovartisNovo NordiskPfizerPharmaceuticalPricingResearchRoche

Global rheumatology market controlled by Enbrel, Humira and Remicade

24-12-2012

The global rheumatology therapeutics market has been forecast to increase at a compound annual growth…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyCelebrexEnbrelGlaxoSmithKlineGlobalHumiraMarkets & MarketingPfizerPharmaceuticalRemicadeTakeda PharmaceuticalsUloric

Abbott launches Sucampo's Amitiza in Japan

27-11-2012

US drugmaker Sucampo Pharmaceuticals (Nasdaq: SCMP), and marketing partner health care major Abbott Laboratories…

Abbott LaboratoriesAmitizaAsia-PacificGastro-intestinalsMarkets & MarketingPharmaceuticalSucampo

Bristol-Myers' subcutaneous Orencia OKed in EU; Biologics for RA

07-10-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) announced on Friday that the European Commission has granted…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEnbrelEuropeHumiraMarkets & MarketingNorth AmericaOrenciaPfizerPharmaceuticalRegulation

Abbott Labs sentenced for misbranding drug; fined $500 million

03-10-2012

US health care major Abbott Laboratories (NYSE: ABT) was sentenced by US District Court Judge Samuel…

Abbott LaboratoriesDepakoteFinancialLegalMarkets & MarketingNorth AmericaPharmaceutical

Abbott/Eisai's Humira has emerged as leading psoriasis agent

07-08-2012

For the treatment of psoriasis, Abbott/Eisai's Humira (adalimumab) has displaced Amgen/Stiefel/Pfizer/Takeda's…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyEisaiEnbrelGlobalHumiraImmunologicalsJanssenMarkets & MarketingPfizerPharmaceuticalStelara Injection

Abbott Labs agrees $1.6 billion settlement over Depakote marketing practices

08-05-2012

Ending a four year investigation, US health care major Abbott Laboratories (NYSE: ABT) has reached a…

Abbott LaboratoriesDepakoteFinancialLegalMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

US gastroenterologists see significant growth for Abbott/Eisai’s Humira in ulcerative colitis once indication is approved

29-11-2011

In a recent survey of US gastroenterologists (n=99), BioTrends Research (a Decision Resources company)…

Abbott LaboratoriesBiotechnologyEisaiGastro-intestinalsHumiraMarkets & MarketingNorth AmericaPharmaceuticalRemicade

Back to top